BioMark has recently completed a very encouraging metabolome study that has implication for biomarker signature related to cancer diagnosis. The discovery is being patented.
BioMark is proud to partner and cooperate with National Cancer Institute in Bangladesh and BioMark China in a phase III multi site trial. The trail will involve over 400 subjects and will focus on 4 cancer indications. All the procedures will follow North American regulatory guidelines that were prepared by Saint Boniface Research centre’s regulatory […]